Title |
Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
|
---|---|
Published in |
European Heart Journal, June 2012
|
DOI | 10.1093/eurheartj/ehs157 |
Pubmed ID | |
Authors |
Thomas Davidson, Magnus Husberg, Magnus Janzon, Jonas Oldgren, Lars-Åke Levin |
Abstract |
Patients with atrial fibrillation have a significantly increased risk of thromboembolic events such as ischaemic stroke, and patients are therefore recommended to be treated with anticoagulation treatment. The most commonly used anticoagulant consists of vitamin K antagonist such as warfarin. A new oral anticoagulation treatment, dabigatran, has recently been approved for stroke prevention among patients with atrial fibrillation. The purpose of this study was to estimate the cost-effectiveness of dabigatran as preventive treatment of stroke and thromboembolic events compared with warfarin in 65-year-old patients with atrial fibrillation in Sweden. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 2 | 67% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Denmark | 2 | 1% |
Netherlands | 1 | <1% |
Colombia | 1 | <1% |
Slovenia | 1 | <1% |
United States | 1 | <1% |
Unknown | 143 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 29 | 19% |
Researcher | 20 | 13% |
Student > Bachelor | 19 | 13% |
Student > Ph. D. Student | 16 | 11% |
Student > Doctoral Student | 7 | 5% |
Other | 22 | 15% |
Unknown | 36 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 66 | 44% |
Pharmacology, Toxicology and Pharmaceutical Science | 14 | 9% |
Economics, Econometrics and Finance | 11 | 7% |
Agricultural and Biological Sciences | 5 | 3% |
Social Sciences | 3 | 2% |
Other | 9 | 6% |
Unknown | 41 | 28% |